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 Introduction
Inflammatory glaucoma, also known as uveitic glauco-
ma is a multifactorial process of inflammation that causes 
the rising of intraocular pressure accompanied by morpho-
logical and physiological modifying similar to open angle 
glaucoma. Glaucoma and uveitis were described together 
for the first time in 1813, by Joseph Beer. Later, in 1891, 
Priestley Smith proposed first modern classification of uve-
itic glaucoma [1].  
The overall prevalence of glaucoma in eyes with uve-
itis varies from 10 to 20%, but it is much more common in 
chronic uveitis and can be as high as 46% [2]. , the preva-
lence of uveitis has been estimated at approximately 115 
people per 100000 population. Approximately 20% of uve-
itis patients develop glaucoma. At internation scale, prev-
alence of uveitis has been estimated at 38-730 people per 
100000 worldwide. Approximately 20% of uveitis patients 
develop glaucoma [3].  
The mechanisms by which ocular inflammation causes 
an increase of the intraocular presure (IOP) are not inte-
grally comprehended, and many of the relevant pathways 
and features are still covered with a veil of mystery. In con-
trast with primary glaucoma, where pressure-independent 
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related with increased IOP, although the elevation of IOP 
may happen intermittently. The eyes of uveitic patients are 
defined by complex interactions between the angles (open 
or closed), trabecular outflow, fluctuations in the aqueous 
production and the response to steroids. Regarding the el-
evation of IOP in these individuals, it is mostly attributed to 
the increased outflow resistance, which distorts the equilib-
rium between aqueous production and outflow [4].  
The wide spectrum of variations in the underlying tra-
becular function in different individuals also adds to the 
perplexity of the uveitis. It is expected that the trabecu-
lar meshwork function may be affected while aging and 
therefore older patients are more susceptible to intraocu-
lar inflammation in comparison with younger individuals. 
Probably, the accumulation of pathological alterations sec-
ondary to the chronic inflammatory activity may also be rel-
evant to the IOP rise in older uveitic patients. Interestingly, 
the management of uveitic glaucoma in our patients appears 
to be more difficult and challenging in the younger age 
group. Whereas, younger individuals may have a stronger 
optic nerve that can withstand high pressure for a more ex-
tended period of time, it appears that older patients develop 
severe optic nerve damage even during shorter intervals of 
raised IOP and consequently more visual disabilities [5, 6].  
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Factors increasing intraocular pressure:
1. Concentration of aqueous proteins, inflammatory 
cells, and debris 
2. Trabeculitis
3. T-cells, IL, cytokines and other immune factors
4. Hypersecretion of prostaglandin
5. Genetic background
6. Corticosteroid-induced elevation of IOP
7. Vascula endothelian grown factor (VEGF) and iris 
neovascularization etc.
The levels of aqueous proteins have been found to be 
elevated in uveitic patients, indicating that they may be as-
sociated with the trabecular outflow. Previous studies have 
investigated the role of aqueous proteins during acute in-
traocular inflammation [7, 27–31].   However, due to the 
fact that these studies have explored acute uveitis, it was not 
feasible to define the long-term effect of elevated aqueous 
proteins in uveitic eyes. It is a well-established knowledge 
that the protein concentration in the anterior chamber 
is increased in acute uveitis, causing a drop of trabecu-
lar outflow. This could probably happen more extensively 
in individuals with clinical entities that present with the 
acute rise of IOP [4]. Though it must be underlined that in 
Posner-Schlossman syndrome, which presents with acutely 
raised IOP, the levels activity in the anterior chamber re-
main normally low, implying that other mechanisms (e.g., 
trabeculitis) contribute in the increased IOP. The increased 
number of trabecular precipitates that include proteins, 
inflammatory cells, and debris in the anterior chamber of 
uveitic eyes may decrease trabecular outflow by clogging of 
the trabecular meshwork. Evidence that inflammatory cells 
lead to clogging of the trabecular meshwork derive from 
studies that recorded acute rises in IOP after Nd: YAG la-
ser capsulotomy. Moreover, there is evidence that the acute 
inflammatory processes that follow Nd: YAG laser can also 
lead to chronic ocular hypertension (OHT), underlining 
that the clogging of trabecular meshwork that occurs dur-
ing an episode of intraocular inflammation may have long-
term effects on trabecular outflow and subsequently on 
IOP. Gonioscopy of the trabecular meshwork can reveal its 
obstruction by inflammatory precipitates in several patho-
logical entities, such as in Grant’s syndrome, pseudoexfolia-
tions, and pigmentary glaucoma. The inflammation of the 
trabecular meshwork, which is known as trabeculitis, may 
also cause a rise in IOP. Herpetic uveitis consists one of the 
most characteristic examples. Two older studies by Hogan 
et al. and Townsend et al. have described the histological al-
terations caused in enucleated human eyes and rabbits with 
herpetic inflammation, respectively [4, 7, 8].
Both studies highlighted that trabeculitis could play 
a critical role in the elevation of IOP in uveitis, especially 
when caused by herpes simplex virus (HSV). However, it is 
yet to be defined whether trabeculitis interferes in types of 
uveitic glaucoma with a more chronic course, such as those 
related to Fuch’s heterochromic cyclitis or juvenile idiopath-
ic arthritis (JIA) [4].
Interestingly, T-cells consist the largest cell population 
in the aqueous, vitreous, retina and the uveal tract of uveitic 
patients. More specifically, Th-1 cells might have a substan-
tial contribution in the pathophysiology of uveitis, but their 
role in uveitic glaucoma remains uncertain [9].  A study 
by Murray et al. investigated the aqueous humor obtained 
from patients with and without uveitis during a cataract 
extraction surgery. Individuals with uveitis demonstrated 
an inflammatory response mediated by T-cells. There was 
a prevailing expression of IL-2 and IFN-γ, which are Th-1 
related cytokines and their levels were significantly lower 
in non-uveitic individuals [10]. Nonetheless, the levels of 
proinflammatory cytokines have been associated with the 
activity of inflammatory activity in various types of uveitis. 
Ohira et al. analyzed the effects of factors on the levels of 
aqueous humor proinflammatory cytokines and growth fac-
tors in uveitic eyes. According to the results mean interleu-
kin (IL)-6, IL-8, monocyte chemotactic protein (MCP)-1, 
tumor necrosis factor (TNF)-α and VEGF were found to be 
higher in cases with uveitic glaucoma than those in cataract 
(non-glaucomatous) cases. Additionally, IL-6, MCP-1, and 
VEGF were all higher in uveitic glaucoma than in patients 
with primary open angle glaucoma (POAG). The uveitic 
cases with a history of phacoemulsification indicated higher 
levels of IL-6, IL-8, MCP-1 and PDGF-AB/BB in compari-
son with the phakic eyes. Finally, the presence of cells in 
the anterior chamber was associated with higher levels of 
TNF-α, IL-8 and PDGF-AB/BB. As for PDGF-AB/BB level, 
it was found to be higher in infectious rather than in non-
infectious uveitis [4, 11, 12].
Mechanisms of intraocular pressure elevation in sec-
ondary open angle glaucoma:
1. Trabecular meshwork obstruction is the most com-
mon mechanism and can be caused by: Disruption of the 
blood aqueous barrier, which allows entry of inflammatory 
cells into the aqueous humor and entrapment of normal 
serum components in the aqueous outflow system. Swell-
ing of trabecular lamellae and endothelial cells with both a 
physical narrowing of trabecular pores and dysfunction also 
leads to aqueous outflow obstruction, ultimately leading to 
permanent damage and scarring of the trabecular mesh-
work [13-15].
2. Hypersecretion caused by PGE1- and PGE2-mediated 
increase in the rate of aqueous secretion or by a breakdown 
in blood-aqueous barrier (BAB), with an associated in-
crease in aqueous protein concentration and thus aqueous 
viscosity [16].
3. Corticosteroid-induced elevation of IOP.
Steroid-induced glaucoma is a form of secondary 
open angle glaucoma that results from the use of steroids. 
Corticosteroids are believed to decrease outflow by inhibit-
ing degradation of extracellular matrix material in the tra-
becular meshwork (TM), leading to aggregation of an exces-
sive amount of the material within the outflow channels and 
a subsequent increase in outflow resistance. The amounts 
of glycosaminoglycans, elastin, and fibronectin have been 
shown to increase in tissue culture preparations in response 
to dexamethasone treatment while the levels of tissue plas-
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minogen activator, stromelysin, and the activity of several 
TM metalloproteases have been shown to fall. Furthermore, 
excessive accumulation of glycosaminoglycans has been 
identified in human trabecular meshwork specimens ob-
tained from steroid-responders, confirming similar findings 
in a rabbit model [17, 18]. In support of the evidence for 
extracellular matrix deposition, dexamethasone treatment 
has also been shown to inhibit TM cell arachadonic acid 
metabolism and reduce phagocytic activity. It is hoped that 
recent advances in novel molecular genetic methods will al-
low a better understanding of the mechanisms causing the 
steroid-induced glaucoma. By gene deletion or overexpres-
sion studies, the exact role of individual genes responsible 
for the modulation of meshwork extracellular material may 
be identified in the near future [19]. An increase in the IOP 
related to the corticosteroids that are used for the control of 
inflammatory reactions in uveitis has been recorded in 18–
36% of patients; these individuals are described as steroid 
responders. Clinically, a response to steroids is expected to 
develop within 2 to 6 weeks after starting therapy, but can 
potentially happen at any time.
Shrestha et al. monitored and studied 116 consecutive 
new uveitic patients, recording the IOP at presentation, at 1 
week, 3 and 6 weeks. They recorded that 20% of these eyes 
developed ocular hypertension, which was at a percentage 
of 64.5% attributed to corticosteroids (37.03% of the oral 
group, 14.28% of the posterior sub-tenon group and 8.57% 
of the topical group). The same study indicated that timely 
medical treatment might avert the necessity of early surgical 
intervention for the control of eye pressure [4].  
Interestingly, as a response to decreased pressure gono-
cytes, which consist of fibro-elastic cells in the anterior 
chamber of the normal human eye secrete polymerized mu-
copolysaccharides. This results in swelling of the cells of 
the trabecular meshwork and a subsequent decrease in the 
trabecular outflow. To curtail these effects and reduce IOP 
hyaluronidase breaks down the polymerized mucopoly-
saccharides. However, the release of hyaluronidase may be 
restricted due to the use of steroids, causing inhibition of 
mucopolysaccharides depolymerization. Some studies have 
investigated the genetic background of steroid responders, 
showing that a gene that may play some role is responsible 
for a protein named Myocilin, which is produced by the cells 
of the human trabecular meshwork [20]. Despite the fact 
that there are not any known Myocilin mutations associated 
with steroid responders, it appears that the cells of human 
trabeculum increase the production of Myocilin in response 
to the administration of dexamethasone. Consequently, al-
though genes might contribute in defining steroid respond-
ers more studies are required to confirm this hypothesis [4]. 
Pathogenesis of Neovascular Inflammatory Glaucoma 
(NVG) is unclear too. Extremely high levels of VEGF are 
present in patients with NVG [21]. In addition to VEGF, se-
veral other molecules have been associated with the develo-
pment of NVG, including basic fibroblast growth factor, pla-
telet-derived growth factor, insulin-like growth factor-1 and 
interferon-α [22]. Vascular proliferation first occurs with 
endothelial budding at the capillary level not only of the 
vasculature of the minor arterial circle of the iris but also the 
major arterial circle at the iris base. These endothelial buds 
progress to glomerulus-like vascular tufts, resembling renal 
micro-vasculature. The new vascular tissue is composed of 
endothelial cells without a muscular layer and with little 
adventitial or supportive tissue. The vessels are thin walled 
and tend to be located near or on the iris surface but can be 
seen histologically at any level within the iris. The fibrovas-
cular membrane in neovasularization of the iris (NVI) also 
contains proliferating myofibroblasts with smooth muscle 
differentiation. This clinically transparent and contractile 
membrane causes a flattening and effacement of iris surfa-
ce architecture, ectropion uveae, development of peripheral 
anterior synechiae (PAS) and subsequent secondary angle 
closure [23].  
Most common causes of uveitic glaucoma:
1. Juvenile rheumatoid arthritis is an autoimmune dis-
ease typically affecting children under the age of 16 years 
and lasts more than six months. The uveitis is typically bi-
lateral, nongranulomatous, asymptomatic anterior uveitis, 
usually preceded by arthritis [24].  It has been shown that 
individuals with persistent low-grade uveitis are at a higher 
risk of developing glaucoma. JIA-related glaucoma often oc-
curs with open angles, but secondary angle-closure caused 
by pupillary block as a result of the formation of posterior 
synechiae is relatively common. Apart from glaucoma, the 
main complications that can lead to loss of vision are a cat-
aract, band keratopathy, and cystoid macular edema [25]. 
Regarding medication, the therapeutic scheme includes a 
topical steroid, cycloplegics that may be followed by system-
ic steroid therapy and possibly regional injection of steroids. 
In persistent and more severe cases immunomodulation 
(e.g., methotrexate) can be incorporated in the manage-
ment of the disease, resulting in low toxicity and high ef-
ficacy.  According to recent studies adalimumab, which is an 
anti-TNF-α agent, has shown efficacy in treating refractory 
uveitis in multiple settings, including juvenile idiopathic 
arthritis [26-28]. With regard to the treatment of glaucoma 
patients are initiated on antiglaucoma medications, but in 
complicated and severe cases surgical treatment (e.g., tra-
beculectomy or tube shunt surgeries) may be unavoidable. 
Unfortunately, many of them might require medication 
even after surgery.
2. Fuch’s heterochromic iridocyclitis was first described 
by Fuch in 1906, FHIC is an idiopathic, painless, chronic, 
low-grade iridocyclitis with heterochromia, due to iris stro-
mal atrophy. The typical age of onset is 20 - 40 years of age, 
with men and women affected equally. 
It is typically unilateral, but in 13% of the cases it has 
presented bilaterally [29, 30]. Infiltration of TM by mono-
nuclear inflammatory cells, typically lymphocytes and 
plasma cells, causes rubeosis, trabeculitis, and collapse of 
the Schelmm’s canal, leading to TM obstruction and rise 
in IOP. Interestingly, iris angiography can detect leakage of 
the iris vessels and ischemic alterations of the iris. Reported 
incidence of glaucoma varies from 13-59%, with higher fig-
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ures seen on long-term follow-up. The glaucoma typically 
persists after uveitis has subsided and does not respond to 
steroids. Fuch’s cyclitis rarely causes synechiae formation. 
Unless glaucoma develops, Fuch’s cyclitis is a benign disor-
der and does not require therapy. Use of steroids may only 
accelerate PSC formation and increase IOP [31].
The glaucoma associated with FHI resembles primary 
open-angle glaucoma. Gonioscopic evaluation may reveal 
multiple fine blood vessels, arranged either radially or con-
centrically in the trabecular meshwork. Cataract is a con-
stant feature of FHI, whereas glaucoma has been reported 
to occur in 6-47% of cases. Low-grade inflammation does 
not need treatment with anti-inflammatory or immunosup-
pressive agents [2].
3. Posner-Schlossman syndrome is characterized by a 
number of unusual features, including unilateral involve-
ment, recurrent attacks of often very mild cyclitis, marked 
elevation of IOP, open angle, and occasional heterochromia. 
IOP may elevate up to 40 to 70 mm Hg during an acute epi-
sode. The condition typically affects individuals aged 20-50 
years and resolves spontaneously regardless of treatment [2].
This rise in the eye pressure has been correlated with the 
aqueous levels of prostaglandins and usually resolves spon-
taneously.  The pathogenetic mechanisms have not been 
clarified yet. Some of the possible etiologic factors include 
HSV and cytomegalo virus (CMV) infections, an immuno-
genetic factor that involves HLA-Bw gastrointestinal disease 
and several allergic factors (i.e., eczema, urticaria, asthma, 
rhinitis, contact dermatitis, angioneurotic edema, intoler-
ance to aspirin and food allergies). The prognosis is benign, 
with only exception for the patients that develop glaucoma-
tous alterations, which is recorded in about 25% of cases. 
Clinical findings include small, flat, fine, non-pigmented 
KP detected in the inferior corneal endothelium. In goni-
oscopy, the angle appears to be open with some occasional 
trabecular precipitates.  The therapeutic approach includes 
steroids and antiglaucoma medication (beta-blockers and 
carbonic anhydrase inhibitors). It has been shown that oral 
indomethacin, prostaglandin inhibitors and subconjuncti-
val polyphloretin (prostaglandin antagonist) are effective in 
lowering the IOP during acute attacks. Surgical treatment is 
indicated in patients that glaucoma persists after maximal 
medical treatment [4].
4. The development of secondary glaucoma consists 
the most common complication of herpetic uveitis. It has 
been reported that 28–45% of patients with HSV keratou-
veitis demonstrate transient increased IOP and 10–54% 
may present with uveitic glaucoma. Disciform keratou-
veitis and necrotic stromal keratitis are associated more 
commonly with elevated IOP than epithelial keratitis [32]. 
Active iridocyclitis accompanied by an acute increase in eye 
pressure are the main features of herpetic infection and in 
most cases, HSVs or VZVs are the etiologic factors. These 
spikes in the IOP occur as a result of the trabecular mesh-
work inflammation, similarly to hypertensive episodes 
of Posner-Schlossman syndrome that has been described 
above.
This explains why the IOP returns to normal levels while 
responding to topical corticosteroids. It must be underlined 
though, that the elevated IOP can occur secondarily to the 
obstruction and swelling of the trabecular meshwork. Epi-
sodes of herpetic uveitis are typically unilateral, acute and 
in severe cases may present with hyphema, hypopyon, fibrin 
deposition and formation of anterior synechiae [4].
Conclusions
1. Inflammatory glaucoma is a multifactorial pathology 
that needs a careful diagnosis and therapeutical approach in 
order to obtain a good management of inflammatory pro-
cess and intraocular pressure. 
2. There are a lot of pathological pathways that influence 
the evolution of inflammatory glaucoma and make treat-
ment more difficult.
3. Previous years, glaucoma treatment has significantly 
improved, but to better understand pathogenesis of uveitic 
glaucoma more scientific studies are necessary.
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